Frank Jaksch - Chromadex Corp Co-Founder, CEO and President and Director

CDXC Stock  USD 7.44  0.19  2.49%   

CEO

Mr. Frank L. Jaksch is no longer Chief Executive Officer, Director of ChromaDex Corporationrationration., effective June 22, 2018. He is a cofounder of the Company and has served as a member of Board since February 2000. Mr. Jaksch served as Chairman of the Board from May 2010 to October 2011 and was its CoChairman from February 2000 to May 2010. Mr. Jaksch currently serves as our Chief Executive Officer. Mr. Jaksch oversees research, strategy and operations for the Company with a focus on scientific and novel products for pharmaceutical and nutraceutical markets. From 1993 to 1999, Mr. Jaksch served as International Subsidiaries Manager of Phenomenex, a life science supply company where he managed the international subsidiary and international business development divisions
Age 56
Address 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
Phone310 388 6706
Webhttps://www.chromadex.com
Jaksch earned a B.S. in Chemistry and Biology from Valparaiso University.

Chromadex Corp Management Efficiency

As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.17. At present, Chromadex Corp's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.6 M, whereas Total Assets are forecasted to decline to about 28.4 M. Chromadex Corp's management efficiency ratios could be used to measure how well Chromadex Corp manages its routine affairs as well as how well it operates its assets and liabilities.
Chromadex Corp currently holds 3.28 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Chromadex Corp has a current ratio of 2.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Chromadex Corp's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 10 records

CEO Age

Paul KangExicure
62
Paul HastingsNkarta Inc
64
Mark ManfrediIkena Oncology
53
Nevan JDRezolute
57
Matthias SchroffExicure
56
David CampbellJanux Therapeutics
64
BAO BChEliem Therapeutics
48
PharmD MBACentury Therapeutics
N/A
Richard CunninghamAnebulo Pharmaceuticals
53
Jon CongletonMineralys Therapeutics, Common
61
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. ChromaDex Corporation is headquartered in Los Angeles, California. Chromadex Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people. Chromadex Corp (CDXC) is traded on NASDAQ Exchange in USA. It is located in 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024 and employs 106 people. Chromadex Corp is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Chromadex Corp Leadership Team

Elected by the shareholders, the Chromadex Corp's board of directors comprises two types of representatives: Chromadex Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chromadex. The board's role is to monitor Chromadex Corp's management team and ensure that shareholders' interests are well served. Chromadex Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chromadex Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kendall Knysch, Head Partnerships
Heather Blarcom, Senior Secretary
Brianna Gerber, Senior Director of FP&A, IR Contact Officer
Andrew Shao, Senior Affairs
Frank Jaksch, Co-Founder, CEO and President and Director
Chu Yan, Managing Pacific
Ozan CFA, CFO Officer
Robert Fried, Independent Director
James Lee, Principal CFO
David Kroes, Senior Matters
Jason Campbell, Senior Development
Alex Worsham, Vice Communications
Tom Shumaker, Managing Advisors
Fadi Karam, Chief Officer
Carlos Lopez, Senior Counsel

Chromadex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chromadex Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Chromadex Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromadex Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromadex Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromadex Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.02
Revenue Per Share
1.215
Quarterly Revenue Growth
0.312
Return On Assets
0.0051
Return On Equity
0.0482
The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.